2025-10-16T08:48:57-04:00 2024-12-31 WITHUMSMITHBROWNPC 6101 BOLLINGER CANYON RD STE 400 SAN RAMON CA 94583 990 2024-01-01 465727883 GRACE SCIENCE FOUNDATION % GRACE SCIENCE FOUNDATION GRAC 6507464591 873 SANTA CRUZ AVENUE SUITE 200 MENLO PARK CA 94025 MATTHEW R WILSEY PRESIDENT 6507464591 2025-11-15 true true RICHARD RUVELSON P00234075 9252779100 2025-11-15 2024 2025-03-06 01:10:19Z MATTHEW R WILSEY 873 SANTA CRUZ AVENUE SUITE 2 MENLO PARK CA 94025 943011 false X www.gracescience.org X 2014 CA SEE PART III LINE 1 7 7 0 0 0 0 783225 869699 0 0 43401 73312 0 0 826626 943011 1133449 1342330 0 0 0 0 0 0 0 155725 177056 1289174 1519386 -462548 -576375 2790274 2224370 42997 1004 2747277 2223366 X THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESESARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTNADING AND TREATMENT OF THIS CONDITION, FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES. false false 452697 452697 Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter) Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define biomarker endpoints for use in therapeutic trials. This study is led by Dr. Bernhard Suter, MD, a child neurologist and medical geneticist. The study is collecting longitudinal measures of movement concurrently with clinical and biomarker measures to define aspects of gait and movement that are most affected in the disorder, characterize progression of the disease, select clinical features for performing longitudinal assessments, and inform clinical endpoint development for therapeutic trials. 352945 352945 Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model to test phenotypic rescue using candidate small molecule therapies (both novel and approved drugs). 203574 203574 THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (YAN LAB) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival. 80637 80637 The University of North Carolina (Hantman Lab) 68025 68025 Charles River Laboratories 49108 49108 Boston Children's Hospital (Yu Lab) 27695 27695 Hilltop Lab Animals Inc. 24241 24241 Albert Einstein College of Medicine (Kaushik Lab) 23869 23869 Purdue University (Rochet Lab) 20356 20356 Pharmaron, Inc 19321 19321 Universitry of Utah (Chow Lab) 10115 10115 Standford University 9747 9747 University of Houston 19000 0 Bioagilytix Labs 13904 0 Transnetyx 10481 0 Wuxi Apptec 5369 0 MedChem Express LLC 381868 333114 1391084 true true false false false false false false false false false false false false false false false false false false true true false false false false false true false false false false false false false false false false false false false false false false false false true 3 0 true 0 false false false false false false false false false false false false false false X 7 7 true false false false false true false false false false false true false false false false false false false CA X X GRACE SCIENCE FOUNDATION 6507464591 873 SANTA CRUZ AVENUE SUITE 200 MENLO PARK CA 94025 X Matthew Wilsey President 0.0 0.0 X X 0 0 0 Egon Durban Chief Financial Officer 0.0 0.0 X X 0 0 0 KEN DRAZAN Secretary 0.0 0.0 X X 0 0 0 Pete Briger Director 0.0 0.0 X 0 0 0 Chelsea Clinton Director 0.0 0.0 X 0 0 0 J Taylor Crandall Director 0.0 0.0 X 0 0 0 Elle Stephens Director 0.0 0.0 X 0 0 0 0 0 0 0 false false false 0 869699 869699 0 73312 0 0 73312 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 943011 0 0 73312 1342330 1342330 0 0 0 0 0 0 0 0 0 0 779 779 0 17420 17420 0 0 0 99200 99200 5000 5000 2717 2717 645 645 0 0 559 559 0 0 0 0 0 0 SHIPPING FEES 1782 1782 TAX EXPENSE 200 200 PROGRAM EXPENSES 48754 48754 1519386 1391084 128302 0 352830 142773 2437444 2081597 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2790274 2224370 42997 1004 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 42997 1004 X 0 0 0 0 0 0 2747277 2223366 2790274 2224370 -576375 52464 X false false false X 1447474 1325647 1206450 783225 869699 5632495 0 0 1447474 1325647 1206450 783225 869699 5632495 2543020 3089475 6706 1466 29778 43401 73312 154663 0 0 5787158 0.53385 0.60408 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true East Asia and the Pacific 0 0 Program Services RESEARCH 10481 0 0 0 0 10481 10481 false false false false false false true CHARLES RIVER LABORATORIES 251 BALLARDVALE STREET WILMINGTON MA 01887 061397316 501(c)(6) 68025 NGLY1 THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTE 5323 HARRY HINES BLVD DALLAS TX 75390 756002868 GOVERNMENT 203574 NGLY1 (YAN LAB) ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVENUE BRONX NY 10461 830621846 501(c)(3) 24241 NGLY1 (KAUSHIK LAB) HILLTOP LAB ANIMALS INC 131 HILLTOP DR SCOTTDALE PA 15683 251153656 27695 NGLY1 BAYLOR COLLEGE OF MEDICINE ONE BAYLOR PLAZA BCM 200 HOUSTON TX 77030 741613278 501(c)(3) 452697 NGLY1 (JAFAR-NEJAD LAB) PURDUE UNIVERSITY 610 PURDUE MALL WEST LAFAYETTE IN 47907 366002041 501(c)(3) 23869 NGLY1 UNIVERSITY OF HOUSTON 4800 CALHOUN ROAD HOUSTON TX 77204 746001399 115 9747 NGLY1 PSYCHOGENICS INC 215 College Rd PARAMUS NJ 07652 141989159 352945 NGLY1 STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(c)(3) 10115 NGLY1 UNC CHAPEL HILL 250 E Franklin St Chapel Hill NC 27514 566001393 501(c)(3) 80637 NGLY1 Boston Children's Hospital 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(c)(3) 49108 NGLY1 PHARMARON 201 EAST JEFFERSON STREET SUITE 30 LOUISVILLE KY 40202 208419781 20356 NGLY1 University of Utah 201 S PRESIDENTS CIR RM 406 SALT LAKE CITY UT 84112 876000525 115 19321 NGLY1 8 5 Part I Description of Procedure for Monitoring Use of Funds * BEFORE FUNDING A PRINCIPAL INVESTIGATOR, THE FOUNDATION REQUIRES A DETAILED PROPOSAL WITH OBJECTIVES AND MILESTONES. * THE PROPOSALS ARE REVIEWED BY THE FOUNDATION AND SCIENTIFIC ADVISORY BOARD. * THE PROPOSALS ARE OFTEN REVISED SEVERAL TIMES TO GET THE CORRECT FIT. * Once funded, each principal investigator submits a written summary every quarter. * This update is two to three pages in length. * The reports discuss progress, highlight roadblocks and identify where they need help. *THE FOUNDATION STEPS-IN WHERE APPROPRIATE TO MAKE SURE OBJECTIVES AND MILESTONES ARE MET. * IN ADDITION TO QUARTERLY REPORTS, THE FOUNDATION HOLDS A MONTHLY CONFERENCE CALL WHERE TWO TO THREE PRINCIPAL INVESTIGATORS PRESENT THEIR LATEST WORK. * BEYOND THE ABOVE TWO INITIATIVES, THE FOUNDATION HOLDS ONE TO TWO IN-PERSON MEETINGS PER YEAR. * DR. KEVIN LEE (CHIEF SCIENTIFIC OFFICER), DR. SELINA DWIGHT (PROGRAM MANAGER), AND MATT WILSEY(PRESIDENT) CONTACT RESEARCHERS AND PRINCIPAL INVESTIGATORS ON A REGULAR BASIS VIA EMAIL, PHONE, OR ONE ON ONE MEETINGS. THE PRESIDENT ENSURES THAT EVERY DOLLAR IS USED TO SUPPORT THE GRACE SCIENCE FOUNDATION'S MISSION. PART II: THE FOUNDATION REQUESTS AND OBTAINS TO THE BEST OF THEIR ABILITY THE FEIN'S FROM ORGANIZATIONS IT PROVIDES GRANT FUNDING. FORM 990, PART III, LINE 1: THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESEARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTANDING AND TREATMENT OF THIS CONDITION, AND FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES Baylor College of Medicine NGLY1 Natural History Study (Bernhard Suter)Team is conducting a natural history study to define the clinical spectrum of the disease and its progression, and define biomarker endpoints for use in therapeutic trials. This study is led by Dr. Bernhard Suter, MD, a child neurologist and medical geneticist. The study is collecting longitudinal measures of movement concurrently with clinical and biomarker measures to define aspects of gait and movement that are most affected in the disorder, characterize progression of the disease, select clinical features for performing longitudinal assessments, and inform clinical endpoint development for therapeutic trials. EXPENSES $452,697. INCLUDING GRANTS OF $452,697. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES Psychogenics Inc. Team has imported and is analyzing mouse and rat models of NGLY1 Deficiency for testing of candidate therapies. Team has conducted several studies using an NGLY1 knockout rat model to test phenotypic rescue using candidate small molecule therapies (both novel and approved drugs). EXPENSES $352,945. INCLUDING GRANTS OF $352,945. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES The University of Texas Southwestern Medical Center (Yan Lab) Team continues work generating and characterizing several mouse models of NGLY1 Deficiency, including models in which the gene is inactivated in certain tissues and conditionally after birth. These mouse models have allowed them to characterize neurological phenotypes including neuronal loss, neuropathological changes, inflammation, sensory and motor defects, and disease associated biomarkers, all of which are also observed in NGLY1 Deficiency patients These animal models provide a foundation for testing candidate therapies, including gene therapies and small molecule drugs. The team has also found that NGLY1 Deficiency in mice triggers a specific innate immune pathway mediated by the cGAS/STING pathway. Using genetic and pharmacological approaches, the team has uncovered three different targets that can be modulated to reduce disease associated phenotypes and improve survival. EXPENSES $203,574. INCLUDING GRANTS OF $203,574. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES The University of North Carolina (Hantman Lab) Team has utilized a mouse model on NGLY1 Deficiency to analyze directed movement behavior and identify the affected brain circuits responsible for the movement phenotypes charcateristic of NGLY1 Deficiency. The studies involve training wild type and Ngly1-deficient mice to perform a "reach-grab" task, comparing the task performance and movement dynamics between typical and affected animals, and recording from specific brain circuits while the animals perform the task. Identified changes will help to better understand the neural basis of the NGLY1 Deficiency movement disorder, define the neural circuits that must be targeted to treat the disease, and establish a platform to test potential therapies. EXPENSES $80,637. INCLUDING GRANTS OF $80,637. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES Charles River Laboratories Team has imported and is maintaining a colony of Ngly1 knockout rats for use in evaluating therapies to treat NGLY1 Deficiency. This knockout model has been a key foundation to test adeno-associated virus (AAV)-mediated gene delivery for rescue of disease-associated phenotypes and has supported an investigational new drug (IND) application to the FDA for an NGLY1 Deficiency gene therapy clinical study. Team has also conducted a study to monitor clinical phenotypes and collect biological samples in homozygous mutant and heterozygous (carrier) NGLY1 knockout rats across the lifespan from birth to eighteen months of age, and has continued to produce Ngly1 KO animals for use in in vivo drug testing studies. EXPENSES $68,025. INCLUDING GRANTS OF $68,025. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES Boston Children's Hospital (Yu Lab) TEAM HAS CONCEIVED AND TESTED METHODS TO USE DESIGNER ANTISENSE OLIGONUCLEOTIDES (ASOS) TO INHIBIT POTENTIAL TARGETS FOR NGLY1 THERAPY DEVELOPMENT. THIS RESEARCH HAS DEVELOPED CELLULAR MODELS TO MEASURE INHIBITION OF A SPECIFIC GENE TARGET WHOSE INACTIVATION HAS BEEN SHOWN TO R ESCUE NGLY1 LOSS. PILOT SCREENS WERE CONDUCTED AND OPTIMIZED ASOS HAVEBEEN IDENTIFIED. TEAM IS RESEARCHING METHODS TO ASSESS RESCUE OF NGLY1 DEFICIENCY PHENOTYPES UPON ASO TREATMENT. EXPENSES $49,108. INCLUDING GRANTS OF $49,108. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES HILLTOP LAB ANIMALS, INC. TEAM HAS IMPORTED AND ESTABLISHED A COLONY OF NGLY1 KNOCKOUT MICE FOR USE IN TESTING THERAPIES TO TREAT NGLY1 DEFICIENCY. A BREEDING COLONY HAS BEEN ESTABLISHED, AND MUTANT PHENOTYPES HAVE BEEN CHARACTERIZED. THIS MODEL SYSTEM HAS BEEN USED TO TEST DRUG CANDIDATES FOR THEIR ABILITY TO RESCUE NGLY1 DEFICIENCY-ASSOCIATED NEUROLOGICAL SYMPTOMS AND FOR GENETIC STUDIES TO TEST WHETHER BLOCKING OTHER PATHWAYS (INCLUDING FBXO6) HAS POTENTIAL TO TREAT NGLY1 DEFICIENCY. EXPENSES $27,695. INCLUDING GRANTS OF $27,695. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES ALBERT EINSTEIN COLLEGE OF MEDICINE (KAUSHIK LAB) TEAM IS TESTING THE HYPOTHESIS THAT DEFECTS IN NGLY1 FUNCTION LEADS TO THE IMPAIRMENT OF CELLULAR PROTEOSTASIS PATHWAYS THAT RECOGNIZE AND CLEAR MISFOLDED AND AGGREGATED PROTEINS AND DEFECTIVE ORGANELLES. USING NGLY1 KNOCKOUT RAT AND MOUSE TISSUES, NGLY1 MUTANT CELL LINES, AND NGLY1 DEFICIENCY PATIENT FIBROBLASTS, THE TEAM HAS OBSERVED SIGNIFICANT IMPAIRMENT IN MACRO- AND CHAPERONE MEDIATED-AUTOPHAGY AND DEFECTS IN LYSOSOMAL BIOGENESIS. THESE RESULTS HIGHLIGHT THE POTENTIAL OF DRUGS THAT TARGET THE AUTOPHAGY-LYSOSOME PATHWAY TO REVERSE CELLULAR DEFECTS ASSOCIATED WITH NGLY1 DEFICIENCY. THE TEAM HAS BEGUN EVALUATING DRUG-LIKE CHEMICAL MODULATORS OF THE AUTOPHAGY-LYSOSOMAL SYSTEM FOR THEIR ABILITY TO REDUCE CELLULAR PROTEOTOXICITY IN NGLY1 DEFICIENCY MODELS. EXPENSES $24,241. INCLUDING GRANTS OF $24,241. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES PURDUE UNIVERSITY (ROCHET LAB) TEAM IS DEVELOPING AND EMPLOYING CELLULAR MODELS TO TEST WHETHER NGLY1 AND ITS SUBSTRATE NFE2L1 HAVE A ROLE IN MODULATING CELLULAR STRESS AND PREVENTING OR CLEARING PROTEIN AGGREGATES IN THE BRAIN. THESE STUDIES ARE TESTING WHETHER LOSS OR DYSFUNCTION OF THE NGLY1-NFE2L1 PATHWAY MAY SENSITIZE NERVE CELLS TO OXIDATIVE OR PROTEIN MISFOLDING STRESS, LEADING TO NEURONAL DAMAGE AND NEURODEGENERATION. IN ADDITION, THE TEAM IS TESTING THE IDEA THAT ENHANCING NGLY1-NFE2L1 ACTIVITY CAN PREVENT OR SLOW NEURONAL LOSS USING CELLULAR MODELS OF PARKINSON'S DISEASE, A NEURODEGENERATIVE DISORDER ASSOCIATED WITH OXIDATIVE STRESS AND PROTEIN AGGREGATION. THESE STUDIES AIM TO UNDERSTAND THE CAUSE OF NEUROTOXICITY IN RARE AND COMMON NEURODEGENERATIVE DISORDERS, EXPLORE MECHANISMS SHARED BETWEEN NGLY1 DEFICIENCY AND PARKINSON'S DISEASE, AND PROVIDE INSIGHTS FOR THE DEVELOPMENT OF DISEASE-MODIFYING NEUROPROTECTIVE THERAPIES. EXPENSES $23,869. INCLUDING GRANTS OF $23,869. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES PHARMARON, INC TEAM HAS CONDUCTED PHARMACOLOGY STUDIES TO SUPPORT IN VIVO TESTING OF SMALL MOLECULE THERAPIES FOR NGLY1 DEFICIENCY. EXPENSES $20,356. INCLUDING GRANTS OF $20,356. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES UNIVERSITRY OF UTAH (CHOW LAB) TEAM HAS DEVELOPED AND IMPORTED MODEL ORGANISM AND HUMAN CELLULAR MODELS OF NGLY1 DEFICIENCY, CHARACTERIZED THEIR ABNORMALITIES AND BEGUN TO USE THESE TO INVESTIGATE CANDIDATE THERAPEUTIC TARGETS OF THIS RARE DISEASE. IN PARTICULAR THE TEAM IS TESTING PREVIOUSLY IDENTIFIED DRUG HITS AND INHIBITORS OF GLYCOGEN SYNTHASE 3-BETA (GSK3B) IN CELLULAR MODELS OF NGLY1 DEFICIENCY, AND IN FLY AND MOUSE MODELS OF NGLY1 DEFICIENCY. EXPENSES $19,321. INCLUDING GRANTS OF $19,321. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES BIOAGILYTIX LABS - vendor has conducted biomarker and immune profiling of NGLY1 Deficiency patients in support of NGLY1 Deficiency natural history studies. EXPENSES $19,000. INCLUDING GRANTS OF $0. REVENUE $0. TRANSNETYX - vendor has provided genotyping services to support animal breeding and functional studies at Hilltop Lab Animals and Psychogenics, Inc. EXPENSES $13,904. INCLUDING GRANTS OF $0. REVENUE $0. WUXI APPTEC - vendor has synthesized and characterized small molecule drug candidates for in vivo studies. EXPENSES $10,481. INCLUDING GRANTS OF $0. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES STANFORD UNIVERSITY DIXON AND BERTOZZI LABORATORIES) TEAM HAS CHARACTERIZED THE ROLE OF FERROPTOSIS, A FORM OF CELL DEATH ASSOCIATED WITH OXIDATIVE STRESS, IN THE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY. THIS STUDY HAS ESTABLISHED THAT LOSS OF NGLY1 OR ITS SUBSTRATE NFE2L1 SENSITIZES CELLS TO FERROPTOSIS, AND THIS FERROPTOSIS SENSITIVITY CAN BE REVERSED BY EXPRESSION OF AN ACTIVATED FORM OF NFE2L1 MIMICKING THAT GENERATED BY NGLY1-CATALYZED PROTEIN MODIFICATION. THESE STUDIES MAY HELP EXPLAIN THE CAUSES OF CELL DYSFUNCTION AND LOSS IN NGLY1 DEFICIENCY AND SUGGEST POTENTIAL TARGETS FOR CANDIDATE THERAPY DEVELOPMENT. EXPENSES $10,115. INCLUDING GRANTS OF $10,115. REVENUE $0. FORM 990, PART III, LINE 4D, OTHER PROGRAM SERVICES UNIVERSITY OF HOUSTON - Team has conducted a pilot movement disorder study to systematically and quantitatively assess movement disorder characteristics of individual patients with NGLY1 Deficiency. EXPENSES $9,747. INCLUDING GRANTS OF $9,747. REVENUE $0. MEDCHEM EXPRESS LLC - vendor has provided small molecule compounds for in vivo and in vitro studies. EXPENSES $5,369. INCLUDING GRANTS OF $0. REVENUE $0. FORM 990, PART VI, SECTION A, LINE 2: THE PRESIDENT OF THE FOUNDATION HAS IMMATERIAL OWNERSHIP INTEREST, IN THE INVESTMENTS OF FORTRESS AND SILVERLAKE, WHICH ARE MANAGED BY TWO OF THE DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A: THE PRESIDENT OF THE FOUNDATION HAS AUTHORITY TO ELECT ONE OR MORE MEMBERS OF THE GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 8A: THE GOVERNING BODY OF THE FOUNDATION DID NOT MEET DURING THE YEAR. FORM 990, PART VI, SECTION A, LINE 8B: THE FOUNDATION DOES NOT HAVE ANY COMMITTEES. FORM 990, PART VI, SECTION B, LINE 11B: PRIOR TO FILING FORM 990, THE FOUNDATION'S PRESIDENT WILL REVIEW THE FORM. FORM 990, PART VI, SECTION C, LINE 18: AVAILABLE UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19: AVAILABLE UPON REQUEST.